Project Grant HT94252410744
Award Date
7/15/24
Completion Date
7/14/27
Dollars Obligated
$698K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Australia
Similar Awards
This $494,851 federal Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program supports the Murdoch Children's Research Institute (MCRI), a non-profit research organization based in Australia, to use patient-derived stem cell models to determine the molecular mechanisms driving neurofibromatosis type 1 (NF1)-associated neurodevelopmental disorders. The 3-year project, running from Aug 2024 to Jul 2027, will leverage MCRI's...
This federal Project Grant award from the Defense Health Agency, under the Military Medical Research and Development program (CFDA 12.420), provides $1,366,365.00 to The Children's Hospital of Philadelphia (CHOP) to conduct a research study titled "BRAIN CHARTS IN CHILDREN AND ADOLESCENTS WITH NEUROFIBROMATOSIS TYPE 1". The study aims to advance healthcare for children by improving the understanding of brain development in those with neurofibromatosis type 1, a genetic disorder that...
This $713,818 Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research by the Research Institute at Nationwide Children's Hospital in Columbus, Ohio to characterize novel patient-specific modeling systems for NF2 disease research and therapeutic testing. The project will be conducted from September 1, 2024 through August 31, 2027. The Research Institute has extensive experience delivering federal research...
The Defense Health Agency awarded a $1,249,009 Project Grant to the Research Institute at Nationwide Children's Hospital under the Military Medical Research and Development program (CFDA 12.420). The grant, awarded on August 15, 2023, funds a 4-year project titled "MORE EFFECTIVE, KEEPING IT SAFE: REPEAT OHSV TREATMENT FOR GLIOMA" to conduct medical research and development related to improving treatments for glioma, a type of brain cancer. As a non-profit research institute, the...
The Defense Health Agency awarded a $1,528,727.00 Project Grant to Children's Research Institute, a subsidiary of Children's National Medical Center, to develop SGT-53, a novel nanomedicine that crosses the blood-brain barrier and augments immunotherapeutic response in pediatric brain cancers. This grant, funded through the Military Medical Research and Development program (CFDA 12.420), supports basic, applied, and advanced biomedical research to transform healthcare for Service Members and the...
The Department of Defense, through the Military Medical Research and Development program (CFDA 12.420), awarded a $858,033 Project Grant to the Children's Hospital Medical Center in Cincinnati, Ohio. The grant, titled "TARGETING SCHWANN CELL-IMMUNE INTERACTIONS IN NEUROFIBROMATOSIS TYPE 1", will fund research focused on improving treatment approaches for neurofibromatosis type 1, a genetic disorder that causes tumor growth in the nervous system. The grant award period runs from...
The Department of the Army Medical Command awarded $1.393 million to the Children's Research Institute under the Military Medical Research and Development federal grant program (CFDA 12.420) to support an early-phase study evaluating MEK and MDM2 inhibition in patients with neurofibromatosis type 1 and premalignant and malignant peripheral nerve sheath tumors. The Children's Research Institute will conduct the clinical trial through September 2026 to investigate medical solutions for...
The University of Manchester was awarded a $616,695 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to conduct research on brain charts in children and adolescents with neurofibromatosis type 1. The 3-year grant, awarded on July 15, 2024, will support the university's efforts to advance understanding of the neurological impacts of this genetic disorder. The research aims to develop improved diagnostic tools and inform...
The Defense Health Agency awarded $603,000 to the Massachusetts General Hospital under the Military Medical Research and Development federal grant program (CFDA 12.420) to support the project "CLINICAL AND MRI PREDICTORS OF INTERNAL NEUROFIBROMA GROWTH IN NEUROFIBROMATOSIS TYPE 1" from September 30, 2021 through September 29, 2024. This project grant will fund research at Massachusetts General Hospital to investigate clinical and MRI predictors of internal neurofibroma growth in...
The Defense Health Agency awarded a $819,080 Project Grant to The University of Texas M.D. Anderson Cancer Center to evaluate how maternal dietary exposure affects neurodevelopment and cognition in neurofibromatosis type 1 (NF1) under the Military Medical Research and Development program (CFDA 12.420). The University of Texas M.D. Anderson Cancer Center will conduct research into medical solutions for the battlefield and innovative healthcare for service members and the public by investigating...